Given the phenotypical and physiological variations in XLH (e.g. in FGF23 levels, phosphate levels and degree of skeletal involvement), it is expected that, for individual patients, different doses of burosumab may be required to provide optimal clinical outcome, which is why dose titration is recommended (16). The gene discussed is FGF23; the disease is X-linked hypophosphatemia.